Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Jincheng Pharmaceutical Group Co., Ltd (300233.SZ)
Zibo, CN
Shandong Jincheng Pharmaceutical Group Co., Ltd., together with its affiliated companies, focuses on the global research, development, manufacturing, and distribution of Cephalosporin intermediates. The Group's extensive product line includes active pharmaceutical ingredients (APIs), biopharmaceutical products, various medical intermediates, specialty fine chemicals, and final dosage form medications. Additionally, it diversifies its operations by offering animal nutrition and healthcare products, as well as providing contract manufacturing (CMO) and contract development and manufacturing (CDMO) services. Established in 2004, the company is headquartered in Zibo, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.92% | -9.38% | -15.34% | -14.01% | -22.02% | -6.08% | -15.12% | -33.54% | -36.24% | -44.97% | +28.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-19.4% Q1'26: +3.9% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-76.9% Q1'26: +66.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+5.7% ★ Q1'26: +7.9% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+3.1% Q1'26: +10.4% (vs Q1'25)
-
ROIC Chemicals: +3.4%+1.5% Q1'26: +8.3% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+0.2% Q1'26: -1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.31× ★ Q1'26: 0.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|
| Revenue |
3.51B
est: 4.52B (-22.4%)
|
3.54B
est: 4.52B (-21.7%)
|
3.37B
est: 5.13B (-34.3%)
|
| EBITDA |
625.22M
est: 540.82M (+15.6%)
|
557.10M
est: 540.82M (+3.0%)
|
604.87M
est: 827.65M (-26.9%)
|
| EBIT |
373.89M
est: 178.59M (+109.4%)
|
251.62M
est: 178.59M (+40.9%)
|
288.03M
est: 374.74M (-23.1%)
|
| Net Income |
273.37M
|
174.71M
|
196.78M
|
| SGA |
996.39M
est: 1.25B (-20.6%)
|
1.03B
est: 1.25B (-17.5%)
|
842.74M
est: 1.43B (-41.0%)
|
| EPS |
0.71
|
0.45
|
0.52
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 37.4K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 146.6K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 69.4K | 0.29% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 6.3K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 14.3K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 706.2K | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 48.6K | 0.28% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 714.1K | 0.05% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 5.4K | 0.10% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.1K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dong He | Accounting Supervisor | — | — |
| Hui Wang | Vice President & Director | — | male |
| Jiaquan Li | President & Chairman | — | male |
| Jing Liu | Financial Director | — | female |
| Xi Cheng Zhang | Vice President | — | male |
| Xi Li Cui | Vice President & Director | — | male |
| Xiaogang Zhu | Vice President & Secretary of the Board of Directors | — | male |
| Zhongzheng Zhang | Vice President & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300233.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
